Goto

Collaborating Authors

press release


Mastercard buys digital identity firm Ekata for $850 million

ZDNet

Mastercard said it will acquire Ekata for $850 million in a deal that will bolster its identity verification technology. Ekata's application programming interfaces (APIs) and tools are used by merchants, marketplaces and financial firms across multiple industries. Ekata's platform provides artificial intelligence enhanced risk scoring, indicators and data attributes. The purchase of Ekata will also bolster Mastercard's digital identity and security framework. Ekata offers a bevy of identify verification services to prevent fraud.


IBM to acquire myInvenio with an eye on AI-enabled automation

#artificialintelligence

During the coronavirus pandemic, digital transformation and automation efforts have accelerated as organizations look to streamline workflows and reduce operational costs. On Thursday, IBM announced a definitive agreement to acquire Italy-based process mining software company, myInvenio. "Digital transformation is accelerating across industries as companies face increasing challenges with managing critical IT systems and complex business applications that span the hybrid cloud landscape," said Dinesh Nirmal, general manager, IBM Automation. The move highlights IBM's investments to provide an AI-enabled automation suite "one-stop shop" for organizations, the company said, with capabilities such as robotic process automation, document processing and process mining among others. IBM said the acquisition will provide companies with "data-driven software" in areas such as sales, production and accounting and could help organizations identify processes for potential AI-enabled automation.


Clarify Health scores $115M in series C funding to grow AI-powered data analytics platform

#artificialintelligence

Enterprise analytics company Clarify Health has secured $115 million in series C funding to scale its self-service healthcare analytics cloud and business software. Clarify Health combines longitudinal data for more than 300 million "unique patient lives" from government and commercial claims, electronic health records (EHRs) and prescriptions, according to the company. These data can help healthcare professionals manage population health and commercialize pharmaceutical and biotechnology products. "By linking CMS claims data with commercial claims, EHR, prescription and socioeconomic data, our models are trained on large cohorts and a more complete picture of each patient's longitudinal healthcare journey," Clarify Health CEO Jean Drouin, M.D., told Fierce Healthcare. The San Francisco-based company was launched in 2015 and has raised $178 million to date, according to Crunchbase.


An A.I.-Powered ETF? Look No Further than 'AMOM'

#artificialintelligence

Investors can use artificial intelligence in their portfolios with assets like the QRAFT AI Enhanced U.S. Large Cap Momentum ETF (AMOM). AMOM is an actively-managed exchange traded fund that aims to provide investors with long-term capital appreciation by utilizing a proprietary artificial intelligence system to select large-capitalization U.S. stocks to be held in the portfolio. The fund seeks to achieve its investment objective by investing at least 80% of its net assets, plus the amounts of any borrowings for investment purposes, in securities of U.S.-listed large-capitalization companies. Just like a sailboat needs wind to move, traders need momentum in order to play price action. That's the impetus for AMOM's methodology, which focuses on equities exhibiting strong momentum.


Domo Achieves AWS Machine Learning Competency Status in Applied AI

#artificialintelligence

Domo (Nasdaq: DOMO) today announced that it has achieved Amazon Web Services (AWS) Machine Learning Competency status in the new Applied Artificial Intelligence (Applied AI) category. This designation recognizes that Domo has demonstrated deep experience and expertise in building or integrating ML solutions on AWS. AWS Partners in the AWS Partner Network (APN) recognized as part of the AWS Machine Learning Competency expansion help customers take advantage of intelligent solutions for the business, from creating, automating, and managing end-to-end ML workflows to modernizing applications with machine intelligence. The AI and ML driven applications are maturing rapidly and creating new demands on enterprises. AWS is keeping pace and continuously evolving AWS Competency Programs to provide customers an ability to engage enhanced AWS Partner technology and consulting offerings.


Microsoft Certified: Azure AI Fundamentals was issued by Microsoft to Victor Nwoguru.

#artificialintelligence

Earners of the Azure AI Fundamentals certification have demonstrated foundational knowledge of machine learning (ML) and artificial intelligence (AI) concepts and related Microsoft Azure services.


Parsons Unleashing Artificial Intelligence to Enhance Decision Making, Solve Problems

#artificialintelligence

Parsons Corporation (NYSE: PSN) is developing and deploying artificial intelligence (AI) across a wide array of federal solutions and critical infrastructure projects to solve our customer's most challenging problems, produce actionable intelligence, and improve the user experience. Data analytics, AI, and edge computing are ingrained in company offerings across all business units. For example, the company developed an AI-enabled weapon-target pairing algorithm, with initial tests showing outstanding accuracy and speed results; produced an electronic warfare (EW) planning optimization tool-set named TEMPO (Tactical Electronic Warfare Machine Learning Planning Optimization); and recently won a classified research and development contract to develop constellation task scheduling algorithms based on organically developed AI technology. "Parsons' artificial intelligence capabilities align with our customer's vision by improving situational awareness, decision-making, the safety of operating equipment, streamlining business processes, and protecting critical infrastructure," said Ricardo Lorenzo, chief technology officer for Parsons. "By combining our AI technical expertise with our operational understanding of the all-domain environment and critical infrastructure markets, we're working closely with our customers to develop leap-ahead technology that empowers operators at the tactical edge and beyond. We're also developing differentiated capabilities that ensure the efficiency and security of existing energy and water networks."


Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031

#artificialintelligence

Forecasts by Application (Drug Discovery, Precision Medicine, Medical Imaging & Diagnostics, Research), by Technology (Machine Learning, Other Technologies), by Offering (Hardware, Software, Services), by Deployment (Cloud, On-Premises) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI Companies AND COVID-19 Recovery ScenariosNew York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031" - https://www.reportlinker.com/p06061831/?utm_source=GNW How Adoption of Artificial Intelligence Impacting Pharmaceutical Industry? The global pharmaceuticals industry is in the throes of transition, both clinical trials and regulatory approvals have been challenged by the proliferation of specialized drugs catering to smaller patient groups. In order to boost results in drug discovery, clinical trials, and research and development, the pharmaceutical and life sciences companies are switching to robotic process control, artificial intelligence and machine learning. All these factors are anticipated to propel demand for artificial intelligence in pharmaceutical across the globe. Artificial Intelligence Anticipated to Revolutionize Several Aspects of Pharmaceutical Industry The way drugs are made, prescribed and ingested today will be standardized by artificial intelligence. Many facets of the pharmaceuticals and life sciences industry will also be revolutionized but will not heal sickness or replace physicians. Understanding the main aim of artificial intelligence, which is to improve human capability and accomplishment instead of challenging it, would dispel much of the technology’s concerns and put out its excellent ability to serve humanity. Which Factors are Fueling AI in Pharmaceuticals Industry Growth? . Growing Complexity of Modern Pharmacology . Growing Demand for Viable Therapeutic Candidates . Improves Overall R&D Productivity . Concerns Associated with Rising Capital Requirements in Drug Discovery . Increasing Awareness Related to Artificial Intelligence Among Pharmaceutical Manufacturers Which Factors are Restraining Growth? . Lack of Skilled Professionals . Limited Availability of Datasets UNIQUE COVID-19 VARIATIONS- only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop - no matter how COVID-19 affects the economy. To access the data contained in this document please email contactus@visiongain.com How do prominent players strengthen their position throughout the world? You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks. Discover how to stay ahead Our 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AI in Pharmaceuticals Market. See how to exploit the opportunities. Forecasts to 2031 and other analyses reveal the commercial prospects . In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. . You find original analyses, with business outlooks and developments. . Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments. Discover sales predictions for the world market and submarkets Application . Drug Discovery . Precision Medicine . Medical Imaging & Diagnostics . Research Technology . Machine Learning . Other Technologies Offering . Hardware . Software . Services Deployment . Cloud . On-Premises In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 13 leading national markets: By Region (Segmental Breakdown for All the Regions) . North America - U.S. - Canada . Europe - Germany - France - UK - Italy - Spain - Rest of Europe . Asia Pacific - China - Japan - India - Rest of Asia Pacific . RoW Need industry data? Please contact us today. Leading companies and the potential for market growth Overall world revenue for AI in Pharmaceuticals Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. Prospects for established firms and those seeking to enter the market- including company profiles for 16 of the major companies involved in the AI in Pharmaceuticals Market. Some of the companies profiled in this report include are Microsoft Corporation, NVIDIA Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Biosymetrics, Euretos, Insitro, Cyclica, Biovista, and OWKIN, INC. Key Questions Answered by this Report . What is the current size of the overall global AI in Pharmaceuticals market? How much will this market be worth from 2021 to 2031? . What are the main drivers and restraints that will shape the overall AI in Pharmaceuticals market over the next ten years? . What are the main segments within the overall AI in Pharmaceuticals market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why? . What factors will affect that industry and market over the next ten years? . What are the largest national markets for the world AI in Pharmaceuticals? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031? . How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031? . Which are the leading companies and what are their activities, results, developments, and prospects? . What are the main trends that will affect the world AI in Pharmaceuticals market between 2021 and 2031? . What are the main strengths, weaknesses, opportunities, and threats for the market? . How will the global AI in Pharmaceuticals market evolve over the forecasted period, 2021 to 2031? . How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth? Read the full report: https://www.reportlinker.com/p06061831/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


IBM acquires myInvenio to add business process automation tools, analytics

ZDNet

Here's a look at how the cloud leaders stack up, the hybrid market, and the SaaS players that run your company as well as their latest strategic moves. IBM said it will acquire process mining company myInvenio as it aims to automate more business processes. Terms of the deal weren't disclosed. IBM and myInvenio, based in Reggio Emilia, Italy, launched a partnership in November. According to IBM, myInvenio can use its platform to find the best business processes to automate with AI.


Alyce, an AI-based personalised corporate gifting startup, raises $30M – TechCrunch

#artificialintelligence

Swag has a long and patchy history in the world of business. For every hip pair of plaid socks, there are five t-shirts you may never wear, an itchy scarf, a notepad your kids might use, and an ugly mug; and most of all, likely thousands of dollars and lots of time invested to make those presents a reality. Now, a startup that has built a service to rethink the concept behind corporate gifts and make them more effective is today announcing a round of funding to continue expanding its business -- and one sign that it may be on to something is its progress so far. Alyce, a Boston startup that has built an AI platform that plugs into various other apps that you might use to interact and track your relationships with others in your working life -- sales prospects, business partners, colleagues -- and then uses the information to personalise gift recommendations for those people, has raised $30 million, a Series B that it will be using to continue building out its platform, signing up more users, and hiring more people for its team. This round is being led by General Catalyst, with Boston Seed Capital, Golden Ventures, Manifest, Morningside and Victress Captial -- all previous backers -- also participating.